James E Allison

Summary

Affiliation: Kaiser Permanente
Country: USA

Publications

  1. ncbi request reprint Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics
    James E Allison
    Division of Research, Kaiser Permanente Northern California Region, 2000 Broadway, Oakland, CA 94612 2304, USA
    J Natl Cancer Inst 99:1462-70. 2007
  2. doi request reprint Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010
    Lisa J Herrinton
    Kaiser Permanente Northern California, Oakland, CA, USA
    Gastroenterology 143:382-9. 2012
  3. doi request reprint FIT: a valuable but underutilized screening test for colorectal cancer-it's time for a change
    James E Allison
    Division of Research, Kaiser Permanente, Northern California, Oakland, California, USA
    Am J Gastroenterol 105:2026-8. 2010
  4. ncbi request reprint Estimation of the period prevalence of inflammatory bowel disease among nine health plans using computerized diagnoses and outpatient pharmacy dispensings
    Lisa J Herrinton
    Division of Research, Kaiser Permanente Northern California, Oakland, CA 94612, USA
    Inflamm Bowel Dis 13:451-61. 2007
  5. doi request reprint Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005
    Lisa J Herrinton
    Division of Research, Kaiser Permanente Northern California, Oakland, California 94612, USA
    Gastroenterology 137:502-11. 2009
  6. ncbi request reprint Immunochemical fecal occult blood tests for colorectal cancer screening
    James E Allison
    Am J Med 116:498; author reply 498-9. 2004
  7. ncbi request reprint Colon Cancer Screening Guidelines 2005: the fecal occult blood test option has become a better FIT
    James E Allison
    Gastroenterology 129:745-8. 2005
  8. ncbi request reprint Screening tests for colorectal cancer: a menu of options remains relevant
    James E Allison
    University of California San Francisco, San Francisco General Hospital Campus, NH 3D, San Francisco, CA 94110, USA
    Curr Oncol Rep 8:492-8. 2006
  9. ncbi request reprint Stool DNA and occult blood testing for screen detection of colorectal neoplasia
    David A Ahlquist
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Intern Med 149:441-50, W81. 2008

Detail Information

Publications9

  1. ncbi request reprint Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics
    James E Allison
    Division of Research, Kaiser Permanente Northern California Region, 2000 Broadway, Oakland, CA 94612 2304, USA
    J Natl Cancer Inst 99:1462-70. 2007
    ..Thus, improving the sensitivity of FOBT should make colon cancer screening programs that use these tests more effective...
  2. doi request reprint Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010
    Lisa J Herrinton
    Kaiser Permanente Northern California, Oakland, CA, USA
    Gastroenterology 143:382-9. 2012
    ..The relationship between inflammatory bowel disease (IBD) and the incidence and mortality of colorectal adenocarcinoma (CRC) has not been evaluated recently...
  3. doi request reprint FIT: a valuable but underutilized screening test for colorectal cancer-it's time for a change
    James E Allison
    Division of Research, Kaiser Permanente, Northern California, Oakland, California, USA
    Am J Gastroenterol 105:2026-8. 2010
    ....
  4. ncbi request reprint Estimation of the period prevalence of inflammatory bowel disease among nine health plans using computerized diagnoses and outpatient pharmacy dispensings
    Lisa J Herrinton
    Division of Research, Kaiser Permanente Northern California, Oakland, CA 94612, USA
    Inflamm Bowel Dis 13:451-61. 2007
    ..There are few contemporary estimates of prevalence rates for inflammatory bowel disease (IBD) in diverse North American communities...
  5. doi request reprint Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005
    Lisa J Herrinton
    Division of Research, Kaiser Permanente Northern California, Oakland, California 94612, USA
    Gastroenterology 137:502-11. 2009
    ..The management of inflammatory bowel disease (IBD) has become increasingly complicated, and it is unknown whether poor outcomes (prolonged steroid use, hospitalizations, and surgery) have declined in the general population...
  6. ncbi request reprint Immunochemical fecal occult blood tests for colorectal cancer screening
    James E Allison
    Am J Med 116:498; author reply 498-9. 2004
  7. ncbi request reprint Colon Cancer Screening Guidelines 2005: the fecal occult blood test option has become a better FIT
    James E Allison
    Gastroenterology 129:745-8. 2005
  8. ncbi request reprint Screening tests for colorectal cancer: a menu of options remains relevant
    James E Allison
    University of California San Francisco, San Francisco General Hospital Campus, NH 3D, San Francisco, CA 94110, USA
    Curr Oncol Rep 8:492-8. 2006
    ..In this review we discuss the rationale for caution in designating one screening test as "the best" and present information on how new stool and serum tests can be used effectively to screen for CRC...
  9. ncbi request reprint Stool DNA and occult blood testing for screen detection of colorectal neoplasia
    David A Ahlquist
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Intern Med 149:441-50, W81. 2008
    ..Stool DNA testing is a new approach to colorectal cancer detection. Few data are available from the screening setting...